Sugi Predict

Sugi Predict / Compounds / SCHEMBL1543477

SCHEMBL1543477

SCHEMBL1543477

COC(=O)c1cc(NS(C)(=O)=O)ccc1C=Cc1cc(-c2ccc(C)[nH]c2=O)cc(C(C)(C)C)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.57
▸ CRBN Q96SW2 1/20 0.39
▸ CHEK1 O14757 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ DAPK3 O43293 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ FYN P06241 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ RET P07949 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ MET P08581 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ PRKACA P17612 1/20 0.37
▸ LTK P29376 1/20 0.37
▸ GRK5 P34947 1/20 0.37
▸ KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2130343 1.00 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL2128650 0.93 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL2128644 0.93 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL2130203 0.92 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL2130207 0.92 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL1542952 0.87 CYP3A4 (0.76) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL1764952 0.87 CYP3A4 (0.76) CYP3A4CRBNCHEK1AURKADAPK3
SCHEMBL2127697 0.86 CYP3A4 (0.75) CYP3A4CRBNBRD4IKBKBCHUK
SCHEMBL2127702 0.86 CYP3A4 (0.75) CYP3A4CRBNBRD4IKBKBCHUK
SCHEMBL2127429 0.85 CYP3A4 (0.57) CYP3A4CRBNCHEK1AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 — — US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 — — EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 — — EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 — — WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 — — US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 — — US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 — — EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CRBN 1397/4885CHEK1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.